GlassScriptPhysician profile
Gregory S Cheatham
NPI 1003844754
$11,265.83
in general payments reported to CMS, 2019-2025
59 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $1,089 · 2021: $1,939 · 2022: $2,136 · 2023: $1,704 · 2024: $1,395 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,702.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,019.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $773.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $621.45 | 2020-2025 | Rexulti |
| Lilly USA, LLC | $509.66 | 2019-2025 | Mounjaro, Jardiance |
| Amgen INC. | $444.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $422.43 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $364.41 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $361.73 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $340.26 | 2019-2023 | Xarelto |
| Indivior INC. | $300.53 | 2019-2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $299.77 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.67 | 2022-2025 | Caplyta |
| Pfizer INC. | $278.19 | 2019-2025 | |
| Abbott Laboratories | $273.57 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cheatham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.